As biotechnology continues to advance, biotherapeutics for psychiatric disorders are becoming the forefront of research and treatment. However, the development of biotherapeutics is a complex and time-consuming process. Ace Therapeutics understands this challenge and is committed to utilizing our expertise and preclinical development capabilities to bring your biological drug to market faster. We offer a comprehensive range of services and support designed to assist you in overcoming any challenges you may encounter during the various stages of antipsychotic preclinical development. Whether it is drug screening, safety assessment, or biomarker studies, we can provide expert guidance to ensure that your program moves forward efficiently and smoothly.

Overview of Therapeutic Biologics for Psychiatric Disorders

Biologics are a class of drugs derived from living organisms or their products. They differ from conventional drugs, which are made from synthetic chemicals. Currently, microbial therapies, nucleic acid-based therapies, gene therapies, cellular therapies, and other biotherapeutics show promise in the treatment of mental illness. These therapies typically target the biological basis of psychiatric disorders and attempt to alleviate symptoms or restore normal function by modifying or regulating biochemical processes in the brain. Some examples of this include:

• Stem cell therapy is being investigated as a new way to treat schizophrenia.
• Probiotics, live biotherapeutic products, have been shown to positively impact depression, anxiety, bipolar disorder, and schizophrenia by reducing inflammation, improving gut microbiota, and balancing gut neurometabolites.

Fig. 1 Proposed microbiota-targeted interventions for mental health. (Berding, K.; et al., 2022)

Ace Therapeutics is committed to leveraging our platform technologies to support the full spectrum of innovation in biological therapies for psychiatric disorders. Focusing on the following areas, we offer our clients a full range of services from target screening to preclinical development to help them accelerate the development of innovative therapies:

• Microbiome therapy development services for psychiatric disorders
• Protein-based antipsychotic drug development services
• Nucleic acid-based antipsychotic drug development services
• Cell therapy development services for psychiatric disorders
• Gene therapy development services for psychiatric disorders

Our Preclinical Development Capabilities

Ace Therapeutics' team of experts has extensive project experience in biological drug development and preclinical testing and can support clients with a wide range of expertise. With our animal models and advanced technologies, we can support all aspects of biological drug development and testing yet, including:

• Target validation and identification services
• Preclinical screening services
• Preclinical pharmacodynamic evaluation services
• Preclinical toxicology services
• Biodistribution studies and pharmacokinetic analysis services

Our Service Features and Advantages

• Flexible and customizable service solutions based on customer needs and drug characteristics.
• Experienced scientists and technical teams provide comprehensive services at any stage of preclinical drug development.
• A wide range of psychiatric disease models and advanced platform technologies are available to meet the needs of all aspects of biological drug development and testing.
• Accelerate your drug development program in an efficient, cost-saving manner.

Ace Therapeutics is committed to providing our clients with comprehensive services to accelerate the innovation of their biotherapeutics for the treatment of psychiatric disorders. Please contact us to learn more about how we can help you accelerate preclinical drug development and testing of biologics for psychiatric disorders. We look forward to assisting you.

Reference

1. Berding, K.; et al. Microbiota-targeted interventions for mental health. Current opinion in psychiatry. 35.1 (2022): 3-9.